Alvocidib - Tolero Pharmaceuticals

Drug Profile

Alvocidib - Tolero Pharmaceuticals

Alternative Names: Alvocidib hydrochloride; Flavopiridol; HL-275; HMR 1275; IND 46211; L 868275; MDL-107826A; NSC 649890

Latest Information Update: 17 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator sanofi-aventis
  • Developer National Cancer Institute (USA); Tolero Pharmaceuticals
  • Class Antineoplastics; Benzopyrans; Flavonoids; Piperidines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; CDC2 protein kinase inhibitors; Cyclin dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acute myeloid leukaemia; Germ cell and embryonal neoplasms
  • Preclinical Multiple myeloma; Myelodysplastic syndromes
  • No development reported B cell lymphoma; Chronic lymphocytic leukaemia
  • Discontinued HIV infections; Non-small cell lung cancer; Oesophageal cancer; Renal cancer; Reperfusion injury

Most Recent Events

  • 13 Apr 2018 Pharmacodynamics data from a preclinical study in Cancer released by Tolero Pharmaceuticals
  • 27 Feb 2018 AbbVie plans a phase I trial for Acute myeloid leukemia (Combination therapy, Second-line therapy or more) in USA (NCT03441555)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Acute-myeloid-leukaemia(Monotherapy) in USA (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top